glp-1 conference Therapeutics Landscape Explored at #ICR2026 | ICR posted on the topic GLP-1 Medications and the Future

The drug tested was called Lixisenatide, which is a glucagon-like peptide-1 receptor agonist, designed primarily for use in diabetes

Hippocampal neurogenesis: a biomarker for depression or antidepressant effects

The SURPASS-J-combo trial embraced diabetic adults with HbA 1c 7% to 11% and BMI 23 kg/m 2 , stable weight and uncontrolled with therapy of metformin, thiazolidinedione, sulfonylureas, meglitinide, alpha-glucosidase inhibitor or SGLT2-i (81)

Gonzalez F, Rote NS, Minium J, Kirwan JP: Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome

These injections support energy, weight management, and metabolic health and patients who see results often become consistent repeat visitors, supporting practice growth and patient satisfaction